Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has appointed a new chief scientific officer. 9 April 2024
Seaport Therapeutics has become the latest founded entity to be created by PureTech Health, the UK biotech behind Karuna Therapeutics, which was recently acquir 9 April 2024
Japanese pharma company Nippon Shinyaku and privately-held UK small activating RNA (RNAa) therapeutics specialist MiNA Therapeutics have announced a collaborati 5 April 2024
Adding to recent setbacks in the development of Leqembi (lecanemab), US firm Biogen (Nasdaq: BIIB) has revealed a filing for a subcutaneous formulation will be 3 April 2024
A start-up focused on neurology, Neurosterix, has launched with a $63 million series A financing led by Perceptive Xontogeny Venture Fund II. 3 April 2024
Just as MDMA looked to be leading the charge of psychedelics and related compounds towards market for mental health conditions, a does of jeopardy has been thro 28 March 2024
USA-based Praxis Precision Medicines, a biopharma translating genetic insights into therapies for central nervous system (CNS) disorders characterized by neuron 27 March 2024
A South Korean company, AriBio, has announced the signing of exclusive marketing rights for its investigational Alzheimer’s disease drug, AR1001. 27 March 2024
Israel’s Teva Pharmaceutical Industries and Japanese drugmaker Daiichi Sankyo have been called out for breaches of the Association of the British Pharmaceutical 27 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.